CRA was retained by counsel for the Plaintiff in a patent infringement suit involving an antiemetic agent for the prevention of chemotherapy-induced nausea and vomiting as well as acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy. CRA prepared an expert report and provided trial testimony demonstrating commercial success, ultimately leading to a successful outcome and a ruling that that the subject patents were not invalid.
Were shareholders harmed by Senate Bill 21’s amendments to the Delaware General Corporation Law?
Delaware Governor Meyer signed into law Senate Bill 21 (SB21) in March 2025, updating Delaware’s corporate law, with some of the key provisions including safe...